Rakovina Therapeutics Inc. (RKV.V)
TSXV · CAD · Healthcare · Biotechnology
CA$0.175 (+6.06%) as of
Key statistics
- Market cap
- 4.27M
- EPS (TTM)
- -0.3100
- Dividend yield
- 0.00%
- 52-week range
- 0.0850 – 0.3200
- Beta
- -0.24
- Profit margin
- 0.00%
- Analyst target
- CA$0.25
- Volume
- 2.50k
About Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase; and kt-4000 series, which are small molecules engineered to induce targeted DNA damage in tumor cells. The company is also involved in the development of kt-5000 series of brain-penetrant dual ATRmTOR inhibitor drug candidates. It has a strategic collaboration with Variational AI Inc. to develop AI-generated ATR inhibitor compounds; and a non-binding Letter of Intent to form a joint venture to co-develop AI-discovered small-molecule oncology therapies. Additionally, Rakovina Therapeutics Inc. has a strategic collaboration with Celvion Therapeutics to identify novel precision medicine strategies. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Vancouver, BC, Canada
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.